Browsing Tag

Akero Therapeutics

Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating…

Jason Junior Jun 2, 2023

SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet…

Health

Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH

Jason Junior Dec 8, 2022

SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet…

Health

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s…

Jason Junior Nov 7, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet…

Health

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

Jason Junior Oct 12, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet…

Health

In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical…

Jason Junior Sep 13, 2022

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%) 50mg (76%) and 28mg (47%) groups demonstrated NASH resolution without worsening of fibrosis, three to…

Health

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence…

Jason Junior Nov 12, 2021

Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological improvements were evident across all types of…

Health

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of…

Jason Junior Oct 20, 2021

SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced…

Health

Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal…

Jason Junior Jul 8, 2021

SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today…

Health

Akero Therapeutics Presents at the American Diabetes Association’s 81st Scientific Sessions,…

Jason Junior Jun 26, 2021

SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today…